Keyword: Tecentriq

Merck’s Keytruda finally has some immuno-oncology competition in first-line, non-small cell lung cancer, courtesy of Roche.

Roche’s Tecentriq is closing in on a billion-dollar-plus lung cancer market that it can have all to itself.

Bristol-Myers Squibb’s Opdivo failed another small-cell lung cancer trial—and now, its Yervoy combination approval in the field could be in jeopardy.

Roche’s I-O rivals are hurtling toward a showdown in kidney cancer. But the Swiss drugmaker has decided to pull its horse out of the race.

Tecentriq is on its way to becoming the first immuno-oncology drug with an approval in triple negative breast cancer, and that path just got shorter.

In June, Merck upstaged Roche with squamous non-small cell lung cancer data. And thanks to a new nod, it looks like it’ll beat Roche to market, too.

New data showed that Roche’s Tecentriq could help some lung cancer patients live longer. But what they didn’t show may be just as important.

Roche’s Tecentriq is gunning for a first-in-class triple-negative breast cancer nod, and it’s out with data that could help it get the job done.

As a big ESMO 2018 kicks off, here are the studies we're most excited to see.